Conclusion: Compared to placebo, CFA (1TDC™) provides an improvement in knee range of motion and overall function in patients with OA of the knee. CFA (1TDC™) may be an alternative to the use of nonsteroidal anti-inflammatory drugs for the treatment of OA.
Conclusion: Use of a CFA (1TDC™) topical cream is an effective treatment for improving knee ROM, ability to ascend/descend stairs, ability to rise from sitting, walk and sit down, and unilateral balance.
In summary, the results of the present investigation indicate that 30 days of treatment with a topical cream consisting of a blend of cetylated fatty acids (1TDC™) is effective for improving static postural stability in patients with knee OA. The results this study and our previous investigation support the use of cetylated fatty acids (1TDC™) in the treatment of OA. Hopefully, such over-the-counter treatment may enhance the trainability of people with OA in exercise programs, especially with the importance as it related to successful aging.
PRACTICAL APPLICATIONS – Our data provide further support for the use of a topical cream consisting of a blend of cetylated fatty acids (1TDC™) and menthol in the treatment of individuals with arthritis of the knee, elbow, and wrist. In the present investigation, we reported significant improvements in stair-climbing ability, ‘‘up-and-go’’ performance, balance, and range of motion; reductions in pain in individuals with knee OA; significant improvements in dynamic and isometric local muscular endurance; and a reduction in pain in individuals with severe pain in the elbow and wrist. The changes were similar to what we had previously noted. In addition, the use of such topical treatments may allow individuals to better exercise, thereby helping them improve their health and fitness. Strength and conditioning professionals who work with such populations may find that it enhances workout capabilities.
Summary: Topical cream [CFEC (1TDC™) cream (5.6%) and 1.5% menthol] or placebo cream [1.5% menthol, in a cream base] was applied twice/day. CF-PT (1TDC™) provided the fastest and most effective study treatment modality. The addition of CFEC (1TDC™) cream to PT resulted in statistically significant improvements, compared to PL-PT, for reduction of pain, neck disability and life quality indicators. Our results indicate that cetylated derivatives of fatty acids (1TDC™) can effectively reduce pain and symptoms associated with neck MPS, when combined with physical therapy.
ABSTRACT: This study investigated whether 1-TetraDecanol Complex (1TDC™) could improve the quality of life (QOL) in arthritic canines. Small and large breed dogs were enlisted in the study regardless of current arthritic medication. The owner completed a questionnaire to identify QOL characteristics. The veterinarian performed physical assessment on major joint structures. Serum and urine were collected using standard veterinarian practices. Animals were assessed prior to and 30 days after supplementation. Dogs consumed dog chews containing a mixture of 1TDC™, dextrates, desiccated liver and hickory flavor. A standard dose of two chews per 20 pounds per day was established. A total of twenty-seven animals were enrolled with three dropping out (age: 10.52.0 yr.; male: 13 male; female: 11). The veterinarian noted that animals with mild to moderate symptoms seemed to respond more favorably than advanced cases. Subjective comments revealed that 75% of owners noted improvement in their pet’s daily QOL. Common observations were that the animals seemed “happier,” “more energetic” and “to have better temperament.” Information obtained from questionnaires indicated that animals exhibited improved gait, stair climbing and affect. There were no changes in serum or urine markers. In summary, the data presented suggests that 1TDC™ mixture can be used to assist canines with joint health challenges. However, more research is warranted for elucidating the mechanism of action.
In summary, 1-TetraDecanol Complex improved the general disposition and functional ability in dogs suffering from arthritis. These fatty acids (1TDC™) offer an alternative to more traditional therapies for treating arthritis in canines. Click here for study document
Conclusion: Topical application of an esterified monounsaturated fatty acid complex (1TDC™) was found promising in preventing bone loss, inflammatory cell infiltration, and connective tissue destruction in the rabbit periodontitis model. Click here for study document
Conclusion: The findings suggest that topical application of cetylated monounsaturated fatty acid complex (1TDC™) is a potential therapeutic approach in controlling the progression of chronic periodontal disease. Click here for study document
Summary: 1TDC™ group exhibited statistically significant reduction in pocket depth, clinical attachment loss, gingival index and bleeding on probing after treatment at 6 weeks, while placebo group did not show any significant change. Compared to placebo group, 1TDC™ group demonstrated significant reductions in clinical attachment loss, gingival index and bleeding on probing at 6 weeks.